Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal

Article Stock Quotes (2) Comments (0)

Morgan Joseph reiterates a 'Buy' on Nektar Technology (Nasdaq: NKTR), raises price target from $9 to $12.

Morgan analyst says, "Yesterday, Nektar announced a $1.5 billion worldwide license agreement with AstraZeneca (NYSE: AZN) to develop and market NKTR-118 and NKTR-119. Although we had anticipated a transaction, the size of the deal and the quality of the partner has meaningfully increased our confidence in the potential of NKTR-118, and Nektar's technology. Our key takeaway from this deal is that despite its low development-risk profile, Nektar's technology could add substantial value to shareholders."

To see more analyst ratings on NKTR Click Here.

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• UPDATE: Raymond James Downgrades Gevo, Inc. (GEVO) to Market Perform
• UPDATE: Macquarie Downgrades Sprint (S) to Neutral

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

UBS, Morgan Joseph

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?